Article Text

Download PDFPDF

Single-cell RNA sequencing for the study of lupus nephritis
  1. Evan Der1,
  2. Hemant Suryawanshi2,
  3. Jill Buyon3,
  4. Thomas Tuschl2 and
  5. Chaim Putterman1
  1. 1Division of Rheumatology, Albert Einstein College of Medicine, Bronx, New York, USA
  2. 2Laboratory for RNA Molecular Biology, Rockefeller University, New York, USA
  3. 3Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, USA
  1. Correspondence to Dr Chaim Putterman; chaim.putterman{at}einstein.yu.edu

Abstract

Single-cell RNA sequencing (scRNA-seq) has recently undergone rapid advances in the development of this technology, leading to high throughput and accelerating discovery in many biological systems and diseases. The single-cell resolution of the technique allows for the investigation of heterogeneity in cell populations, and the pinpointing of pathological populations contributing to disease. Here we review the development of scRNA-seq technology and the analysis that has evolved with the ever-increasing throughput. Finally, we highlight recent applications of scRNA-seq to understand the molecular pathogenesis of lupus and lupus nephritis.

  • lupus nephritis
  • systemic lupus erythematosus
  • inflammation

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors ED, HS, TT and CP prepared and wrote the manuscript.

  • Funding Funding was provided through grants from the National Institutes of Health (UH2-AR067676, UH2-AR067677, UH2-AR067679, UH2-AR067681, UH2-AR067685, UH2-AR067688, UH2-AR067689, UH2-AR067690, UH2-AR067691, UH2-AR067694, and UM2-AR067678).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.